Key Takeaways & Executive Findings
- •• Gene editing technologies, particularly CRISPR-Cas9, have revolutionized genetic research and therapeutic development. • Recent advances in base editing and prime editing offer improved precision and reduced off-target effects. • Effective delivery systems remain a critical challenge for clinical translation of gene editing therapies. • Ethical and regulatory frameworks must evolve to ensure safe and equitable application of gene editing.
Abstract
Gene editing technology has emerged as a transformative tool in biomedical research and therapeutic development. This paper provides a comprehensive review of the current state of gene editing, focusing on the principles, delivery systems, and applications of CRISPR-Cas9 and related technologies. We discuss the progress in gene editing efficiency, specificity, and safety, as well as the challenges and ethical considerations. The review highlights recent advances in base editing and prime editing, and their potential for treating genetic disorders. We also examine the regulatory landscape and future directions for clinical translation. Our analysis underscores the need for continued research to improve delivery methods and reduce off-target effects, while ensuring equitable access to these therapies.
1. Introduction
Gene editing technology has rapidly evolved over the past decade, enabling precise modifications to the genome of living organisms. The discovery of CRISPR-Cas9 as a programmable nuclease has democratized gene editing, making it accessible to laboratories worldwide. This technology has been widely adopted for basic research, agricultural improvement, and therapeutic development. However, challenges such as off-target effects, delivery efficiency, and ethical concerns remain.
This review aims to provide a comprehensive overview of the current state of gene editing, including the mechanisms of CRISPR-Cas9, base editing, and prime editing. We discuss recent progress in improving editing efficiency and specificity, as well as the development of novel delivery vehicles. We also examine the applications of gene editing in treating genetic diseases, cancer, and infectious diseases. Finally, we address the ethical and regulatory considerations that accompany the translation of these technologies into clinical practice.
Loading authentic research manuscript (Pages 1–5)...
Anonymous (2026). Gene Editing Technology: Research Progress, Applications, and Future Directions. Chinese Journal of New Drugs. https://doi.org/pub_80__articleID_97
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is gene editing?
Gene editing is a technology that allows scientists to modify an organism's DNA, enabling the addition, removal, or alteration of genetic material at specific locations in the genome.
How does CRISPR-Cas9 work?
CRISPR-Cas9 uses a guide RNA to direct the Cas9 enzyme to a specific DNA sequence, where it creates a double-strand break. The cell's repair machinery then introduces mutations or inserts new genetic material.
What are the main challenges in gene editing?
Key challenges include off-target effects, delivery efficiency to target cells, immune responses, and ethical concerns regarding germline editing.
What are the potential applications of gene editing?
Gene editing has applications in treating genetic disorders, developing cancer immunotherapies, creating disease-resistant crops, and advancing basic research.
What is the future of gene editing?
The future involves improving precision and safety, developing better delivery methods, and establishing robust regulatory frameworks to ensure ethical and equitable use.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.